Established in 1977 in Dong Thap Province, Vietnam, Imexpharm has consistently pursued excellence in quality as its unwavering commitment, dedicated to providing exceptional healthcare products of the highest quality, safety, and efficacy for patients and the community. Driven by a commitment to excellence, Imexpharm has, for nearly a half century, consistently invested in research and development, upgraded technology, established modern technical infrastructure, optimized production processes, and invested in human resources to ensure compliance with the most advanced world standards, including EU-GMP. Our dedication is reflected in our current ownership of three EU-GMP factories boasting a total of 11 production lines. This positions Imexpharm as the pharmaceutical manufacturer with the largest cluster of EU-GMP factories and the most EU-GMP production lines in Vietnam. In 2020, Imexpharm received investment from SK Investment, a member of the SK Group, the second-largest economic conglomerate in South Korea and listed in the Global Fortune 500. With a strong financial foundation and international management experience from SK Investment, Imexpharm will become the largest pharmaceutical manufacturing company in Vietnam, helping to meet the domestic and export market demands.